https://www.selleckchem.com/products/a-674563.html
The risk of HPD increased by 20% for every 20% increase in the ΔNLR at 4weeks. Accordingly, an NLR increase at 4weeks (HR 1.79; 95% CI 1.19-2.68) was associated with an increased risk of death, especially among patients with a baseline NLR≥3. The baseline and on-treatment kinetics for the NLR are effective prognostic indicators in nivolumab-treated patients with HCC. This may help to guide patient selection and on-treatment strategies for immunotherapies in advanced HCC. The baseline and on-treatment kinetics for the NLR are effective
Like
Comment
Share
